SkinBioTherapeutics has developed a proprietary technology platform designed to harness the human microbiome to improve skin health and access the emerging market for skin health probiotic products. Importantly the company is transitioning from a development business to a commercial operation, demonstrated by two recent, validating third party agreements. The company is implementing a strategy designed to target a range of significant market opportunities, offering the potential for near term re ....
16 Jul 2020
Cenkos: SkinBioTherapeutics Plc -- Delivering on strategy
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Cenkos: SkinBioTherapeutics Plc -- Delivering on strategy
SkinBioTherapeutics Plc (SBTX:LON) | 9.8 0 0.0% | Mkt Cap: 19.5m
- Published:
16 Jul 2020 -
Author:
Chris Donnellan -
Pages:
29
SkinBioTherapeutics has developed a proprietary technology platform designed to harness the human microbiome to improve skin health and access the emerging market for skin health probiotic products. Importantly the company is transitioning from a development business to a commercial operation, demonstrated by two recent, validating third party agreements. The company is implementing a strategy designed to target a range of significant market opportunities, offering the potential for near term re ....